{"id":"piroxicam-beta-cyclodextrin","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Gastrointestinal upset (dyspepsia, nausea)"},{"rate":"5-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Headache"},{"rate":"3-8","effect":"Dizziness"},{"rate":"1-5","effect":"Gastric ulceration"},{"rate":null,"effect":"Renal impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Piroxicam is a non-selective COX inhibitor that blocks both COX-1 and COX-2 enzymes, thereby reducing the production of pro-inflammatory prostaglandins and providing analgesic, anti-inflammatory, and antipyretic effects. The beta-cyclodextrin complexation enhances the drug's aqueous solubility and absorption, potentially improving its pharmacokinetic profile compared to conventional piroxicam formulations.","oneSentence":"Piroxicam-beta-cyclodextrin is a nonsteroidal anti-inflammatory drug (NSAID) formulated with beta-cyclodextrin to improve solubility and bioavailability, inhibiting cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:20.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Acute musculoskeletal pain and inflammation"}]},"trialDetails":[{"nctId":"NCT03153657","phase":"PHASE3","title":"Piroxicam-beta-Cyclodextrin on Tooth Sensitivity Caused by In-office Bleaching","status":"COMPLETED","sponsor":"Universidade Federal de Sergipe","startDate":"2016-12-13","conditions":"Tooth Sensitivity, Toothache","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ASTHMA"},{"count":1,"reaction":"DRUG EFFECT DECREASED"},{"count":1,"reaction":"FLUID OVERLOAD"},{"count":1,"reaction":"SARCOIDOSIS"}],"_approvalHistory":[],"publicationCount":41,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cycladol (20mg) capsule"],"phase":"phase_3","status":"active","brandName":"Piroxicam-Beta-Cyclodextrin","genericName":"Piroxicam-Beta-Cyclodextrin","companyName":"Universidade Federal de Sergipe","companyId":"universidade-federal-de-sergipe","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piroxicam-beta-cyclodextrin is a nonsteroidal anti-inflammatory drug (NSAID) formulated with beta-cyclodextrin to improve solubility and bioavailability, inhibiting cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation. Used for Rheumatoid arthritis, Osteoarthritis, Acute musculoskeletal pain and inflammation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}